AtaiBeckley
AtaiBeckley Inc. is a clinical-stage biotechnology company developing treatments for mental health disorders, including therapies based on psychedelics, entactogens, and related compounds. The company was founded in November 2025 through the combination of atai Life Sciences N.V. and Beckley Psytech Limited. atai Life Sciences was founded in 2018 and became a publicly listed company in 2021. Beckley Psytech, a private company, was founded in 2019. In December 2025, the combined company redomiciled from the Netherlands to the U.S., incorporated in Delaware and headquartered in New York, NY. The company's shares trade on the Nasdaq stock exchange under the ticker symbol ATAI.
Recent news mentioning AtaiBeckley
- — AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
- — Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.